Technical Background: Temporally Advanced Detection of Physiological Signals

In interventional medical devices and other closed-loop physiological systems, delays in signal detection, processing, and response can reduce overall performance. Certain patho-physiological events are candidates for temporally advanced waveform detection: for signals such as cardiac or brain activity, longer delay generally makes it more difficult to intervene early enough to contain or limit a pathological process such as cardiac fibrillation or an epileptic seizure. Signal Advance technology is being evaluated for potential application to early arrhythmia and seizure detection and intervention, among other uses.

Signal Advance technology may be suited to medical instruments, treatment devices, and electrophysiological interfaces used in the detection, acquisition, and processing of band-limited analog waveforms produced by the body — for example, brainwaves such as the EEG and MEG, neuromuscular potentials such as the EMG, and cardiac rhythms such as the ECG.

Demonstrating reliable, temporally advanced detection of electrophysiological waveforms could, if validated, enable earlier intervention in a pathological event than is currently possible. In real-time applications, Signal Advance technology may help offset signal-processing delays associated with extracting relevant features, potentially improving response time and overall system performance. Using multiple spectrally tuned bands of single-stage circuits in parallel, the technology has the potential to temporally shift overlapping signal elements — such as artifacts or noise — differentially, which may help unmask bioelectric signal components of interest based on their spectral content.

Because unique circuit design is required for each application, development must weigh trade-offs among the temporal advance achieved, the minimum spectral range required, and tolerance for signal distortion. Direct experimental results indicate that overall temporal advance can be increased by cascading multiple circuit stages, provided that distortion and any introduced artifacts are minimized through appropriate filtering and signal conditioning.

For a general overview of Signal Advance Technology and the broader categories of sensors to which it may apply, see Industrial Applications & Markets.

Potential Medical Applications for Signal Advance Technology

Signal Advance is developing and evaluating signal-processing technology intended to reduce the effective delay associated with detecting and responding to changes in physical signals. In medical systems, where sensing, processing, and intervention may occur within a feedback loop, a measurable reduction in signal-related delay could potentially improve responsiveness and overall system performance.

Potential medical applications include:

1. Cardiac rhythm management
2. Neuromodulation and neurostimulation
3. Physiological monitoring and diagnostic instrumentation
4. Neuroprosthetics and human-machine interfaces
5. Physiologically gated imaging and radiation therapy
6. Real-time physiological-signal artifact detection and rejection
7. Closed-loop and responsive therapeutic systems

Medical applications would require application-specific validation. Any performance improvement would need to be demonstrated without adversely affecting signal accuracy, stability, noise, reliability, patient safety, or clinical outcomes.

Cardiac Rhythm Management

Cardiac rhythm management systems monitor the electrical activity of the heart and, when appropriate, deliver pacing or therapeutic stimulation. This field includes:

• Implantable and external pacemakers
• Implantable cardioverter-defibrillators
• Cardiac resynchronization therapy devices
• Cardiac monitoring and diagnostic systems
• Electrophysiology and related control equipment

Because these systems depend on the timely acquisition, interpretation, and response to physiological signals, they represent a potential field of application for Signal Advance technology. Possible areas of investigation include earlier recognition of qualifying signal changes, improved timing within sensing and control pathways, and more responsive closed-loop operation.

Signal Advance technology would not eliminate delays arising from cardiac physiology, electrode-tissue interfaces, therapeutic programming, safety logic, or required signal processing. Its potential value would be limited to a qualifying component of the overall signal-response pathway.

The worldwide cardiac rhythm management device market was estimated at approximately $20.8 billion in 2024. One current market analysis projects growth to approximately $36.2 billion by 2033, representing a compound annual growth rate of approximately 6.4% over the forecast period. [1]

Illustrative example — electrocardiology: Current cardiac-monitoring technology typically acquires multiple consecutive heartbeats to detect anomalous cardiac signals before generating a response, which is necessarily delayed — yet anti-tachycardia therapies are generally most effective when delivered soon after onset. Signal Advance technology is being evaluated as a means of earlier detection of life-threatening cardiac activity, potentially allowing more rapid intervention. Signal components indicative of fibrillation or tachyarrhythmia (F-waves) can be masked by the larger ventricular QRST complex; temporally shifting the F-wave differentially could facilitate its detection, which may be significant given the short time available to distinguish life-threatening ventricular fibrillation from other arrhythmias.

Illustrative example — circuit design trade-offs: The signal characteristics of a given application determine its circuit-design requirements. For an ECG used in an implantable cardioverter-defibrillator, the frequency range of interest is often below 40 Hz and waveshape is important for extracting specific signal features, so circuitry would be designed to provide constant advance and gain through 40 Hz to minimize distortion. By contrast, for ECG-gated imaging or radiation therapy — where only detection of the QRS peak is required — waveshape is less critical, and some signal distortion may be acceptable in exchange for increased peak-detection temporal advance.

Neuromodulation and Neurostimulation

Neuromodulation systems deliver electrical or other forms of stimulation to targeted neural structures. Current and developing applications include:

• Spinal cord stimulation
• Deep brain stimulation
• Vagus nerve stimulation
• Sacral nerve stimulation
• Peripheral nerve stimulation
• Responsive neurostimulation
• Gastric electrical stimulation

These technologies are used or being investigated for chronic pain, movement disorders, epilepsy, urinary and bowel dysfunction, gastroparesis, and other neurological or physiological conditions.

Signal timing can be important in responsive or closed-loop neuromodulation, particularly where stimulation is adjusted using detected physiological activity. If Signal Advance technology can reduce a meaningful portion of the sensing or response delay while preserving waveform integrity, it could potentially support more responsive stimulation, detection, or control.

The worldwide neurostimulation-device market was estimated at approximately $6.3 billion in 2025 and is projected by one research provider to reach approximately $13.9 billion by 2033, representing projected annual growth of approximately 10.3% from 2026 through 2033. [2] A separate analysis estimates the broader neuromodulation market at approximately $6.81 billion in 2025, increasing to approximately $10.68 billion by 2030. [3]

These estimates use different market definitions and should not be treated as directly interchangeable.

Illustrative example — seizure intervention: In epilepsy, seizures typically begin focally, in a small region of the brain, and can become generalized within a fraction of a second. The performance characteristics most critical to seizure suppression and neural pacing are high sensitivity, high specificity, and — most importantly — rapid detection. Earlier detection of epileptiform EEG activity and a faster overall response could potentially improve intervention efficacy.

Illustrative example — neurotherapy: In neurofeedback therapy, EEG signals are detected and interpreted to control the feedback provided to the patient — a form of operant conditioning. Reducing feedback delay could potentially improve the efficacy and efficiency of neurotherapy generally. Most neurofeedback systems operate on EEG signals with spectral content well under 100 Hz, which may make them suitable candidates for evaluation of Signal Advance technology.

Physiological Monitoring and Diagnostic Systems

Medical monitoring systems acquire signals such as:

• Electrocardiographic activity
• Electroencephalographic activity
• Electromyographic activity
• Blood pressure and blood flow
• Respiration and blood-oxygen saturation
• Temperature and metabolic measurements
• Motion and biomechanical activity

Potential applications for Signal Advance technology include time-sensitive monitoring, event detection, alarm generation, signal synchronization, and artifact identification. Any use would require confirmation that the technology does not introduce clinically significant distortion, false detections, missed events, or instability.

Possible opportunities may exist in bedside monitoring, ambulatory monitoring, wearable systems, electrophysiology laboratories, emergency-care equipment, and specialized diagnostic instrumentation.

Closed-Loop and Responsive Therapies

Medical technology is increasingly moving toward systems that sense a physiological condition, analyze the acquired signal, and automatically adjust therapy. Examples include responsive neurostimulation, adaptive deep-brain stimulation, cardiac pacing, automated insulin delivery, rehabilitation systems, and other bioelectronic therapies.

In these systems, total response time can include delays associated with:

• Physiological sensing
• Analog and digital filtering
• Analog-to-digital conversion
• Signal analysis and classification
• Communication between components
• Therapeutic decision logic
• Actuator or stimulation response
• The patient’s physiological response

Signal Advance technology would address only those delay components for which its effect can be technically demonstrated. Its commercial value would therefore depend on whether the improvement is clinically meaningful when evaluated within the complete system.

Imaging, Radiation Therapy, and Signal Synchronization

Many imaging and therapeutic systems synchronize data acquisition or treatment delivery with respiration, cardiac activity, or patient movement.

Potential applications may include:

• Cardiac and respiratory gating
• Motion-compensated imaging
• Image-guided radiation therapy
• Real-time synchronization of sensors and treatment equipment
• Earlier identification of movement or physiological-state changes

Improved signal timing could potentially assist systems in responding more closely to a measured physiological event. However, the benefit would have to be evaluated against the temporal resolution, processing architecture, mechanical response, and safety controls of the complete imaging or therapy system.

Illustrative example — gated imaging: In gated imaging or radiotherapy, trigger signals are used to time image acquisition or radiation delivery to periods of minimal movement — between heartbeats or breaths — and to halt the process when unexpected movement is detected. Movement from respiration or heartbeat can otherwise produce imaging artifact, reducing image quality and potentially requiring additional scans and increased patient exposure. In gated radiation therapy, unexpected respiratory or cardiac movement can result in unintended irradiation of normal tissue or reduced radiation to the targeted tissue; in both applications, halting the process as quickly as possible after unexpected movement is important, and reduced delay in movement detection could potentially improve performance.

Illustrative example — gated radiation therapy: Respiration rates are typically well under 60 breaths per minute (approximately 1 Hz), and motion of the lungs or other organs from respiration presents a movement profile similar to the respiratory cycle. Circuitry could potentially be developed to temporally advance detection of respiratory-related signals by over 0.5 seconds, providing an earlier termination trigger in respiratory-gated radiation therapy — potentially reducing damage to normal tissue and improving targeting accuracy.

Neuroprosthetics and Human-Machine Interfaces

Neuroprosthetic and neural-interface systems translate physiological signals into control commands or deliver information back to the nervous system.

Potential applications include:

• Prosthetic-limb control
• Assistive communication systems
• Brain-computer interfaces
• Functional electrical stimulation
• Rehabilitation robotics
• Sensory-feedback systems

Reduced signal-processing delay may improve perceived responsiveness or control quality in some applications. The significance of that improvement would depend on signal quality, decoding accuracy, system bandwidth, user adaptation, and the response characteristics of the controlled device.

Illustrative example — prosthetics: The processing demands associated with neural interfaces for prosthetic and robotic applications continue to limit cybernetic performance, as long time delays are associated with control and feedback loops. The steps involved in detecting, processing, and interpreting neural signals can result in response delays in advanced prosthetic limbs that are much longer than biological response times; Signal Advance technology is being evaluated as a potential means of temporally advancing signal detection and offsetting some of these processing delays.

Real-Time Artifact Detection and Rejection

Physiological measurements are frequently affected by patient movement, electrode displacement, electrical interference, muscle activity, and other artifacts. Earlier identification of a changing artifact condition could potentially improve signal-quality management and reduce the period during which corrupted data influence monitoring or control decisions.

Potential applications include electrocardiography, electroencephalography, electromyography, wearable monitoring, sleep studies, and motion-sensitive diagnostic equipment. Signal Advance technology would need to operate alongside—not replace—appropriate filtering, classification, and clinical decision safeguards.

Current Market Environment

The cardiac rhythm management and neurostimulation markets have grown substantially since the market information previously presented on this page was published in 2010–2011.

Current third-party estimates indicate:

• A global cardiac rhythm management device market of approximately $20.8 billion in 2024, projected to reach approximately $36.2 billion by 2033. [1]
• A global neurostimulation-device market of approximately $6.3 billion in 2025, projected to reach approximately $13.9 billion by 2033. [2]
• A broader global neuromodulation market estimated at approximately $6.81 billion in 2025, projected to reach approximately $10.68 billion by 2030. [3]

Market estimates vary because research providers may include different product categories, geographic regions, monitoring systems, implantable devices, external devices, accessories, and related services.

These market totals describe the scale of the industries in which Signal Advance technology may have potential applications. They are not estimates of Company revenue or of the market share Signal Advance could obtain.

Industry Participants

Major participants in cardiac rhythm management, neuromodulation, monitoring, and related medical-device markets include Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, GE HealthCare, LivaNova, Medtronic, MicroPort, Philips, Stryker, and other specialized medical-device and neurotechnology companies.

Depending on the application, these organizations and their suppliers could represent potential licensees, development partners, customers, competitors, or strategic acquirers.

The prior page’s references to Guidant and St. Jude Medical are no longer current as independent-company references. Boston Scientific acquired Guidant, while Abbott acquired St. Jude Medical.

Regulatory Considerations

The regulatory pathway for a medical device incorporating Signal Advance technology would depend on the complete device, its intended use, risk classification, technological characteristics, and effect on safety and effectiveness.

A 510(k) submission is used to demonstrate that a device is substantially equivalent to a legally marketed predicate device. A change to an existing device may require a new 510(k) if it could significantly affect safety or effectiveness or if it constitutes a major change in intended use. [4][5]

High-risk Class III devices generally require Premarket Approval, or PMA. Implantable pacemakers, defibrillators, and many other life-supporting or life-sustaining devices are Class III products. Modifications to an approved Class III system may require a PMA supplement rather than a 510(k). [6][7]

Accordingly, it should not be assumed that Signal Advance technology would qualify for a 510(k) or a less burdensome “hybrid 510(k)” process merely because it is adjunctive. The applicable pathway could include:

• 510(k) clearance
• De Novo classification
• Premarket Approval
• PMA supplement
• Investigational Device Exemption
• Another device-specific regulatory process

The determination would ordinarily be made with the medical-device manufacturer, regulatory counsel, and the FDA based on the particular product and proposed claims.

Commercial Opportunity

Signal Advance technology may be most commercially attractive where it can be incorporated into an established medical platform and provide a measurable improvement without changing the platform’s fundamental therapeutic or diagnostic purpose.

Potential commercialization models include:

• Technology licensing
• Joint development with medical-device manufacturers
• Application-specific engineering agreements
• Component or subsystem integration
• Research collaborations
• Strategic partnerships with sensor, semiconductor, or instrumentation companies

The commercial opportunity will depend on:

• Reproducible technical validation
• Demonstration of a clinically meaningful benefit
• Preservation of signal fidelity and system stability
• Patient-safety and risk-management analysis
• Compatibility with existing medical-device architectures
• Regulatory requirements and clinical-evidence needs
• Manufacturing and quality-system requirements
• Patent coverage and freedom to operate
• Reimbursement and healthcare economics
• Acceptance by manufacturers, clinicians, and patients

Signal Advance therefore views the medical-device industry as a potentially valuable application market, not as an established source of revenue. Development should proceed through carefully selected use cases, bench testing, simulation, preclinical evaluation where appropriate, and collaboration with experienced medical-device manufacturers and regulatory specialists.

To inquire about potential medical applications, research collaborations, or licensing and development opportunities, please contact us.

Technology Resources

To download or view the complete Signal Advance Technology document, please visit the Validations page of our website or click here.

Questions about potential medical applications of Signal Advance technology? Contact us.

Sources

1. [Grand View Research—Cardiac Rhythm Management Devices Market]
2. [Grand View Research—Neurostimulation Devices Market]
3. [MarketsandMarkets—Neuromodulation Market, 2025–2030]
4. [U.S. FDA—Premarket Notification 510(k)]
5. [U.S. FDA—When a Device Modification Requires a New 510(k)]
6. [U.S. FDA—Premarket Approval]
7. [U.S. FDA—Regulatory Requirements for Permanent Pacemaker Leads]

Continue to Industrial Market Analysis.